Wikipedia

Buprenorphine/naltrexone

Buprenorphine/naltrexone is an experimental combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor (KOR) antagonist, and naltrexone, a MOR and KOR silent antagonist, which is under investigation for the potential treatment of psychiatric disorders.[1][2] The combination of the two drugs is thought to result in a selective blockade of the KOR and hence fewer MOR activation-related concerns such as euphoria and opioid dependence. It has been found to produce antidepressant-like effects in mice (similarly to the case of buprenorphine alone or in combination with samidorphan)[3][4] and (at a buprenorphine dosage of 16 mg/day but not 4 mg/day) has recently been found to be effective in the treatment of cocaine dependence in a large clinical trial.[5][6]

Buprenorphine/naltrexone
Combination of
BuprenorphineOpioid modulator
NaltrexoneOpioid antagonist
Legal status
Legal status
Identifiers
CAS Number

See also

edit

References

edit
  1. ^ McCann DJ (April 2008). "Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders". Clinical Pharmacology and Therapeutics. 83 (4): 627–30. doi:10.1038/sj.clpt.6100503. PMID 18212797. S2CID 21165673.627-30&rft.date=2008-04&rft_id=https://api.semanticscholar.org/CorpusID:21165673#id-name=S2CID&rft_id=info:pmid/18212797&rft_id=info:doi/10.1038/sj.clpt.6100503&rft.aulast=McCann&rft.aufirst=DJ&rfr_id=info:sid/en.wikipedia.org:Buprenorphine/naltrexone" class="Z3988">
  2. ^ Cordery SF, Taverner A, Ridzwan IE, Guy RH, Delgado-Charro MB, Husbands SM, Bailey CP (July 2014). "A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm" (PDF). Addiction Biology. 19 (4): 575–86. doi:10.1111/adb.12020. PMID 23240906. S2CID 18330823.575-86&rft.date=2014-07&rft_id=https://api.semanticscholar.org/CorpusID:18330823#id-name=S2CID&rft_id=info:pmid/23240906&rft_id=info:doi/10.1111/adb.12020&rft.aulast=Cordery&rft.aufirst=SF&rft.au=Taverner, A&rft.au=Ridzwan, IE&rft.au=Guy, RH&rft.au=Delgado-Charro, MB&rft.au=Husbands, SM&rft.au=Bailey, CP&rft_id=http://opus.bath.ac.uk/32853/1/revised_paper_CPB_21_Oct_submitted_authors_accepted_version.pdf&rfr_id=info:sid/en.wikipedia.org:Buprenorphine/naltrexone" class="Z3988">
  3. ^ Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I (March 2015). "Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice". Psychopharmacology. 232 (5): 907–15. doi:10.1007/s00213-014-3723-y. PMC 4326609. PMID 25178815.907-15&rft.date=2015-03&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326609#id-name=PMC&rft_id=info:pmid/25178815&rft_id=info:doi/10.1007/s00213-014-3723-y&rft.aulast=Falcon&rft.aufirst=E&rft.au=Maier, K&rft.au=Robinson, SA&rft.au=Hill-Smith, TE&rft.au=Lucki, I&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326609&rfr_id=info:sid/en.wikipedia.org:Buprenorphine/naltrexone" class="Z3988">
  4. ^ Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, Lucki I (August 2016). "Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors". Neuropsychopharmacology. 41 (9): 2344–51. doi:10.1038/npp.2016.38. PMC 4946065. PMID 26979295.2344-51&rft.date=2016-08&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946065#id-name=PMC&rft_id=info:pmid/26979295&rft_id=info:doi/10.1038/npp.2016.38&rft.aulast=Falcon&rft.aufirst=E&rft.au=Browne, CA&rft.au=Leon, RM&rft.au=Fleites, VC&rft.au=Sweeney, R&rft.au=Kirby, LG&rft.au=Lucki, I&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946065&rfr_id=info:sid/en.wikipedia.org:Buprenorphine/naltrexone" class="Z3988">
  5. ^ Almatroudi A, Husbands SM, Bailey CP, Bailey SJ (July 2015). "Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice". Journal of Psychopharmacology. 29 (7): 812–21. doi:10.1177/0269881115586937. PMC 5075030. PMID 26045511.812-21&rft.date=2015-07&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075030#id-name=PMC&rft_id=info:pmid/26045511&rft_id=info:doi/10.1177/0269881115586937&rft.aulast=Almatroudi&rft.aufirst=A&rft.au=Husbands, SM&rft.au=Bailey, CP&rft.au=Bailey, SJ&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075030&rfr_id=info:sid/en.wikipedia.org:Buprenorphine/naltrexone" class="Z3988">
  6. ^ Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, et al. (August 2016). "Buprenorphine naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study". Addiction. 111 (8): 1416–27. doi:10.1111/add.13375. PMC 4940267. PMID 26948856.1416-27&rft.date=2016-08&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940267#id-name=PMC&rft_id=info:pmid/26948856&rft_id=info:doi/10.1111/add.13375&rft.aulast=Ling&rft.aufirst=W&rft.au=Hillhouse, MP&rft.au=Saxon, AJ&rft.au=Mooney, LJ&rft.au=Thomas, CM&rft.au=Ang, A&rft.au=Matthews, AG&rft.au=Hasson, A&rft.au=Annon, J&rft.au=Sparenborg, S&rft.au=Liu, DS&rft.au=McCormack, J&rft.au=Church, S&rft.au=Swafford, W&rft.au=Drexler, K&rft.au=Schuman, C&rft.au=Ross, S&rft.au=Wiest, K&rft.au=Korthuis, PT&rft.au=Lawson, W&rft.au=Brigham, GS&rft.au=Knox, PC&rft.au=Dawes, M&rft.au=Rotrosen, J&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940267&rfr_id=info:sid/en.wikipedia.org:Buprenorphine/naltrexone" class="Z3988">


 

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Buprenorphine/naltrexone&oldid=1204944868"